Introduction
Methods
Selection of eligible studies
Study assessment
Data extraction
Statistical analysis
Results
Study characteristics
First author | Year | Study location | Cancer type | Sample size | Source of controls | Genotyping methods |
---|---|---|---|---|---|---|
1. Lu JC | 2006 | USA | SCCHN | 716/719 | HCC | PCR-RFLP |
2. Gil J | 2011 | Poland | CC | 133/100 | HCC | PCR-RFLP |
3. Webb PM | 2005 | Australia | OC | 548/335 | PCC | PCR |
4. Gresner P | 2012 | Poland | SCCHN | 81/111 | PCC | PCR |
5. Seedhouse C | 2004 | UK | AL | 267/186 | PCC | PCR |
6. Jawad M | 2006 | UK | AL | 267/186 | PCC | PCR |
7. Krupa R | 2011 | Poland | CC | 100/100 | HCC | PCR |
8. Sliwinski T | 2010 | Poland | SCCHN | 288/353 | HCC | PCR-RFLP |
9. Hamdy MS | 2011 | Egypt | AL | 50/30 | HCC | PCR-RFLP |
10. Liu L | 2011 | China | AL | 625/704 | HCC | PCR |
11. Romanowicz-MakowskaH | 2012 | Poland | CC | 320/320 | HCC | PCR |
12. WerbouckJ | 2008 | Belgium | SCCHN | 152/157 | HCC | PCR |
13. Romanowicz-MakowskaH | 2011 | Poland | OC | 120/120 | HCC | PCR |
14. Bhatla D | 2008 | USA | AL | 452/646 | PCC | PCR |
15. Voso MT | 2007 | Italy | AL | 160/161 | HCC | PCR-RFLP |
16. Mucha B | 2012 | Poland | CC | 200/200 | HCC | PCR-RFLP |
17. Zhang ZQ | 2009 | China | AL | 166/458 | HCC | PCR-RFLP |
18. Auranen A (UK) | 2005 | UK | OC | 729/847 | PCC | PCR |
18. Auranen A (USA) | 2005 | USA | OC | 326/419 | PCC | PCR |
18. Auranen A (Danish) | 2005 | Denmark | OC | 278/699 | PCC | PCR |
21. Yang L | 2011 | China | AL | 379/704 | HCC | PCR |
22. Rollinson S | 2006 | UK | AL | 479/952 | PCC | PCR |
First author | Year | Case | GC | CC | Control | GC | CC | Case | C | Control | C | HWE |
---|---|---|---|---|---|---|---|---|---|---|---|---|
GG | GG | G | G | |||||||||
1. Lu JC | 2006 | 624 | 91 | 1 | 622 | 96 | 1 | 1339 | 93 | 1340 | 98 | 0.17 |
2. Gil J | 2011 | 100 | 29 | 4 | 73 | 27 | 0 | 229 | 37 | 173 | 27 | 0.19 |
3. Webb PM | 2005 | 457 | 85 | 4 | 971 | 145 | 10 | 999 | 93 | 2087 | 165 | 0.08 |
4. Gresner P | 2012 | 67 | 13 | 1 | 71 | 14 | 2 | 147 | 15 | 156 | 18 | 0.22 |
5. Seedhouse C | 2004 | 210 | 44 | 3 | 166 | 18 | 2 | 464 | 50 | 350 | 22 | 0.08 |
6. Jawad M | 2006 | 210 | 44 | 3 | 166 | 18 | 2 | 464 | 50 | 350 | 22 | 0.08 |
7. Krupa R | 2011 | 61 | 36 | 3 | 36 | 35 | 29 | 158 | 42 | 107 | 93 | 0.003 |
8. Sliwinski T | 2010 | 138 | 145 | 5 | 258 | 64 | 32 | 421 | 155 | 580 | 128 | 0.28 |
9. Hamdy MS | 2011 | 39 | 9 | 2 | 26 | 3 | 1 | 87 | 13 | 55 | 5 | 0.06 |
10. Liu L | 2011 | 72 | 25 | 8 | 511 | 175 | 18 | 169 | 25 | 1197 | 211 | 0.52 |
11. Romanowicz- MakowskaH | 2012 | 51 | 56 | 213 | 91 | 164 | 65 | 158 | 482 | 346 | 294 | 0.57 |
12. Werbouck J | 2008 | 136 | 15 | 1 | 134 | 23 | 0 | 287 | 17 | 291 | 23 | 0.32 |
13. Romanowicz-MakowskaH | 2011 | 13 | 15 | 92 | 33 | 69 | 18 | 41 | 199 | 135 | 105 | 0.07 |
14. Bhatla D | 2008 | 374 | 73 | 5 | 555 | 85 | 6 | 821 | 83 | 1195 | 97 | 0.18 |
15. Voso MT | 2007 | 125 | 33 | 2 | 142 | 18 | 1 | 283 | 37 | 302 | 20 | 0.61 |
16. Mucha B | 2012 | 161 | 34 | 5 | 157 | 37 | 6 | 356 | 44 | 351 | 49 | 0.05 |
17. Zhang ZQ | 2009 | 117 | 47 | 2 | 315 | 123 | 20 | 281 | 51 | 753 | 163 | 0.08 |
18. Auranen A (Danish) | 2005 | 241 | 36 | 1 | 616 | 78 | 5 | 518 | 38 | 1310 | 88 | 0.15 |
18. Auranen A (UK) | 2005 | 642 | 84 | 3 | 745 | 100 | 2 | 1368 | 90 | 1590 | 104 | 0.48 |
18. Auranen A (USA) | 2005 | 270 | 52 | 4 | 357 | 61 | 1 | 592 | 60 | 775 | 63 | 0.34 |
21. Yang L | 2011 | 268 | 101 | 10 | 511 | 175 | 18 | 637 | 121 | 1197 | 211 | 0.52 |
22. Rollinson S | 2006 | 431 | 34 | 1 | 817 | 115 | 4 | 896 | 36 | 1749 | 123 | 0.98 |
Quantitative synthesis
Variables | No.a | Case/Control | GG vs. CC | GC vs. CC | GG+GC vs. CC | GG vs. GC+CC | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR(95% CI) | Pb | P | OR(95% CI) | Pb | P | OR(95% CI) | Pb | P | OR(95% CI) | Pb | P | |||
Total cancer types
| 22 | 6836/8507 | 0.83(0.43–1.59) | 0.00c | 0.57 | 0.90(0.39–2.08) | 0.00c | 0.81 | 0.82(0.39–1.73) | 0.00c | 0.60 | 0.84(0.69–1.02) | 0.00c | 0.08 |
SCCHN | 4 | 1237/1340 | 2.46(1.08–5.61) | 0.50 | 0.03 | 2.20(0.30–16.22) | 0.02 | 0.44 | 2.50(0.76–8.28) | 0.25 | 0.13 | 0.84(0.40–1.75) | 0.00c | 0.64 |
CC | 4 | 753/720 | 0.92(0.08–10.55) | 0.00c | 0.95 | 0.65(0.05–8.08) | 0.00c | 0.74 | 0.79(0.06–10.16) | 0.00c | 0.85 | 1.12(0.53–2.35) | 0.00c | 0.77 |
OC | 5 | 2001/2420 | 0.42(0.10–1.78) | 0.0007 | 0.24 | 0.41(0.06–2.67) | 0.00c | 0.35 | 0.40(0.07–2.18) | 0.00c | 0.29 | 0.80(0.62–1.03) | 0.07 | 0.09 |
AL | 9 | 2845/4027 | 0.82(0.49–1.39) | 0.26 | 0.47 | 1.00(0.59–2.08) | 0.29 | 0.99 | 0.85(0.50–1.44) | 0.25 | 0.60 | 0.82(0.63–1.07) | 0.002 | 0.14 |
Source of controls
| ||||||||||||||
HCC | 13 | 3409/4126 | 0.77(0.30–1.98) | 0.00c | 0.58 | 0.79(0.24–2.60) | 0.00c | 0.70 | 0.74(0.26–2.13) | 0.00c | 0.58 | 0.82(0.60–1.12) | 0.00c | 0.20 |
PCC | 9 | 3427/4381 | 0.93(0.53–1.62) | 0.87 | 0.79 | 1.14(0.64–2.02) | 0.87 | 0.66 | 0.95(0.54–1.67) | 0.88 | 0.87 | 0.88(0.71–1.09) | 0.01 | 0.25 |
Ethnicity
| ||||||||||||||
Asian | 3 | 1170/1866 | 0.92(0.27–3.19) | 0.01 | 0.90 | 0.98(0.28–3.40) | 0.01 | 0.97 | 0.94(0.27–3.26) | 0.009 | 0.92 | 0.94(0.77–1.14) | 0.64 | 0.52 |
Caucasian | 18 | 5616/6611 | 0.80(0.36–1.79) | 0.00c | 0.59 | 0.86(0.31–2.38) | 0.00c | 0.77 | 0.79(0.32–1.95) | 0.00c | 0.61 | 0.83(0.65–1.05) | 0.00c | 0.13 |
African | 1 | 50/30 | 0.75(0.06–8.70) | 0.82 | 1.50(0.10–23.07) | 0.77 | 0.83(0.07–9.54) | 0.88 | 0.55(0.16–1.90) | 0.34 |